Abstract A more complete understanding of the mechanisms that regulate the angiogenic switch, which contributes to the conversion of small dormant tumors to actively growing malignancies, is important for the development of more effective anti-angiogenic strategies for cancer therapy. While significant progress has been made in understanding the complex mechanisms by which integrin avb3 expressed in endothelial cells governs angiogenesis, less is known concerning the ability of avb3 expressed within the tumor cell compartment to modulate the angiogenic output of a tumor. Here we provide evidence that avb3 expressed in melanoma cells may contribute to the suppression of IGFBP-4, an important negative regulator of IGF-1 signaling. Given the multiple context-dependent roles for avb3 in angiogenesis and tumor progression, our novel findings provide additional molecular insight into how avb3 may govern the angiogenic switch by a mechanism associated with a p38 MAPK and matrix metalloproteinases-dependent regulation of the endogenous angiogenesis inhibitor IGFBP-4.
Introduction
Angiogenesis, the process by which new blood vessels arise from preexisting vessels, is thought to play important roles in many normal and pathological events. Tumor angiogenesis may facilitate metastatic disease and in many cases has been correlated with a poor clinical prognosis [1] [2] [3] [4] . Evidence indicates that small tumor lesions may remain dormant and fail to expand beyond a minimal size without a functional vascular network [5] [6] [7] [8] [9] [10] . These studies and others suggest that in order for small tumors to expand, a shift in the expression of angiogenic regulatory molecules may occur, resulting in what has been termed the angiogenic switch [5] [6] [7] [8] [9] [10] .
Recent work has confirmed the utility of anti-angiogenic strategies in treating malignant tumors as indicated by the approval of anti-angiogenic drugs that target growth factor signaling [11] [12] [13] . However, several new studies have demonstrated the complexity involved in targeting secreted pro-angiogenic factors as a therapeutic modality. For example, studies have shown that while inhibition of growth factor signaling pathways or certain matrix metalloproteinases (MMPs) may lead to a reduction in tumor angiogenesis, malignant lesions may circumvent these initial inhibitory activities, contributing to increased tumor cell invasion and poor drug diffusion, ultimately resulting in limited durable responses [14] [15] [16] [17] [18] . These studies along with others are driving the need for a more comprehensive understanding of the mechanisms that regulate pathological angiogenesis in order to fully realize the potential of anti-angiogenic therapy.
Evidence suggests that the local tumor microenvironment plays an important role in controlling the pro-and antiangiogenic balance within tumors [6, [19] [20] [21] [22] [23] [24] . Several studies have provided evidence that alterations in the balance of pro-angiogenic growth factors such as VEGF, FGF-2 and PDGF, proteolytic enzymes such as MMPs and endogenous inhibitors such as TSP-1 and fragments of ECM proteins may govern whether a tumor remains dormant or expands [24] [25] [26] .
Integrins are a family of heterodimeric cell surface proteins composed of non-covalently associated a and b chains that play important roles in establishing communication links between the extracellular microenvironment and cells [6, 27] . Integrins play multiple roles in angiogenesis and may act as functional hubs that integrate streams of molecular information between diverse cellular and non-cellular compartments [6, 27] . While it is well known that integrins can regulate multiple signaling cascades required for angiogenesis, the molecular details by which they coordinate these events are still not completely understood. To this end, pharmacological blockade of integrin avb3 inhibits angiogenesis and tumor growth [27] [28] [29] [30] [31] . However, lack of avb3 in transgenic mouse models enhanced angiogenesis and tumor growth [32, 33] . In other studies, mice expressing signaling deficient b3 integrin exhibited defective pathological vascular development and smaller tumors, which depended on reduced recruitment of bone marrow-derived cells [34] . These findings indicate that the roles of avb3 in governing pathological angiogenesis and tumor progression are complex, and further studies are needed to unravel the functions of this integrin.
Our prior studies have indicated that changes in structure of the ECM may facilitate the creation of a proangiogenic and tumor permissive environment in part by exposing cryptic integrin binding sites for tumor and stromal cells [19, 35, 36] . Given these findings, it is possible that the ECM may contribute to the control of the angiogenic switch. Previous studies suggest that endothelial cell interaction with denatured collagen suppresses expression of IGFBP-4 [37] , an important regulator of IGF-1 signaling and angiogenesis [38] [39] [40] . However, the mechanisms by which cellular interactions with structurally altered collagen regulates IGFBP-4 is not known. Here we provide evidence that avb3 expressed in melanoma cells may contribute to the reduction of IGFBP-4 in part by a p38 MAPK-dependent mechanism that involves elevated levels of MMPs and enhanced degradation of IGFBP-4. Collectively, our novel finding provides new insight into the complex mechanisms by which avb3 may regulate angiogenesis and early tumor development by modulating the angiogenic output of melanoma tumors.
Experimental procedures
Reagents, kits, chemicals and antibodies Bovine serum albumin (BSA), methanol, ethanol, acetone, and OCT embedding compound were all obtained from Sigma (St Louis, MO). Monoclonal antibodies (Mab) LM609 (anti-avb3) and anti-b3 integrin were obtained from Millipore (Bedford, MA). Anti-IGFBP-7 antibody was obtained from Abcam (Cambridge, MA). Anti-IG-FBP-4, anti-MMP-2 antibody (K-20) and anti-tubulin antibodies were from Santa Cruz BioTechnology (Santa Cruz, CA). Antibodies to phosphorylated p38 MAPK and p38 isoforms were from Cell Signaling (Danvers, MA). Normal mouse IgG was obtained from Pierce (Rockford, IL). Anti-CD-31 antibody was obtained from BD Pharmingen (San Jose, CA). HRP-labeled goat anti-mouse and goat anti-rabbit antibodies were from BioSourse (Camarillo, CA). Alexa 488 and 594-conjugated secondary antibodies were obtained from Invitrogen (Carlsbad, CA). MTT proliferation assay kit was obtained from Millipore (Bedford, MA). BrdU cell proliferation assay kit was obtained from Calbiochem (San Diego, CA). P38 MAPK inhibitor (SB202190) was obtained from EMD chemicals (Gibbston, NJ). MMP inhibitor GM6001 was obtained from Millipore (Bedford, MA), and the selective MMP-2 [41] inhibitor ARP 100 was obtained from Cayman Chemical (Ann Arbor, MI). Mab D93 directed to denatured forms of collagen [42] was obtained from TRACON (San Diego, CA). Vector M.O.M Immunodetection Kit was obtained from Vector Laboratories (Burlingame, CA).
Cells and cell culture
Human M21 (avb3-positive) and M21L (avb3-negative) melanoma and parental ECV (avb3-positive) carcinoma cell lines were gifts from Dr. David Cheresh (UCSD, San Diego CA). M21b3-KD cell variant was generated by transfection with b3 integrin specific (ITGB3-shRNA) obtained from Origene Technologies (Rockville, MD). M21BP4 overexpressing tumor cell variant was generated by transfection of the IGFBP-4 full-length expression construct pCMV6-neo vector obtained from Origene Technologies (Rockville, MD). All control cell lines were generated by transfection of cloning vectors without cDNA or target shRNA inserts. Tumor cell variant ECVL (avb3 negative) was generated by 4 rounds of negative FAC sorting with Mab LM609. Tumor cells were maintained in RPMI (Gibco, Grand Island, NY), high glucose supplemented with 10 % fetal bovine serum (FBS), glutamine and penicillin/streptomycin at 37°C with 5 % CO 2 . All cells were maintained as sub-confluent cultures and split 1:4 prior to use. Human umbilical vein endothelial cells (HUVEC) were obtained from Lonza (Walkersville, MD) and cultured in EBM-2 medium in the presence of 2 % FBS and supplements (Lonza). HUVECS were maintained as sub-confluent cultures and used between passages 4-6.
Immunohistochemical and immunofluorescence analysis
Briefly, frozen sections (4 lm) from tumors from each experimental condition were fixed with 50 % methanol and 50 % acetone at -20°C and blocked with 2.5 % BSA in PBS. Tumor sections were subjected to standard hematoxylin and eosin (H&E) staining methods. For analysis of avb3 expression, tumor sections prepared as described above were blocked with 2.5 % BSA in PBS. Next, tissue sections were incubated with mouse on mouse Ig blocking reagent (Vector Laboratories) according to manufactures instruction and then incubated with anti-avb3 Mab LM609 (10 lg/ml). Tissues were washed and incubated with Alexa 594-conjugated anti-mouse secondary antibody (1:500). Photographs were taken at a magnification 200X.
Real-time quantitative RT-PCR
Real-time quantitative RT-PCR was carried out essentially as described [35] . Briefly, equal numbers of tumor cells (1.0 9 10 6 ) were plated and harvested. Total RNA was isolated using Qiagen RNeasy plus kit, (Valencia, CA). Real-time RT-PCR reactions were run in duplicate on a BioRad iQ5 system. Human IGFBP-4 primer sets included 5 0 -GAGCTGGGTGACACTGCTTG-3 0 and 5 0 -CCCACGA GGACCTCTACATCA-3 0 . b2-macroglobulin was used for normalization for all experiments, and primer sets for b2-macroglobulin included 5 00 -GCCTGGAGGCTATCCAGC GTACT-3 0 and 5 0 -ACATGGTTCACACGGCAGGCA-3 0 . Experiments were completed at least 3 times.
Proliferation assays
Equal numbers (1 9 10 3 /well) of sub-confluent melanoma (M21 and M21L) or carcinoma (ECV and ECVL) tumor cell variants were resuspended in proliferation buffer (RPMI plus 1.0 % serum) and added to 96-well assay plates and incubated at 37°C over a 3-day time course. Cell proliferation was quantified using the MTT proliferation assay kit measuring the relative levels of mitochondrial dehydrogenase according to the manufacturer's instructions. For HUVEC proliferation studies, sub-confluent cells (2,000/well) were washed and resuspended in HUVEC growth medium with 2.0 % FBS in the presence or absence 10 ll of 109 concentrated serum-free conditioned medium derived from 48-h cultures of equal numbers (5.0 9 10 6 ) of either M21 or M21L melanoma cells. Cell proliferation was measured 24 h later using the BrdU proliferation assay kit according to the manufacture's instructions. All growth assays were preformed at least 3 times.
Murine tumor growth assays
Briefly, sub-confluent cultures of human M21, M21L, M21b3-KD, M21Cont melanoma cells or ECV and ECVL carcinoma cells were harvested, washed and resuspended in sterile PBS. Human M21 melanoma cell variants (0.5 or 5.0 3 10 6 ) or ECV carcinoma cell variants (5.0 3 10 6 ) were injected subcutaneously into female nude mice in a total volume of 100 ll. For initial primary tumor growth analysis, tumor cells were allowed to grow from 4 to 19 days. At the end of the incubation period, tumor volume was estimated using the formula V = L 2 9 W/2, where V = volume, L = length and W = width [25, 29] . All experiments were preformed at least twice with 5-8 animals per condition.
Tumor angiogenesis assays
To quantify tumor-associated angiogenesis, microvascular density counts were performed as previously described [19, 36] . Briefly, tumors (N = 3-7) from each experimental condition were dissected, washed and embedded in OTC and snap-frozen. Frozen sections (5-6-lm) were fixed by incubation for 10 min in a solution of cold 50 % methanol and 50 % acetone. Tissues were blocked with 2.5 % BSA. Tissues were incubated with anti-CD31 antibody in 2.5 % BSA in PBS for 2 h at 37°C. Tissues were washed and incubated with Alexa568-conjugated secondary (1:500 dilution in 1.0 % BSA in PBS). The number of CD31-positive tumor vessels was counted in either ten, 2009 microscopic fields or from five, 1009 microscopic fields from three individual tumors from each experimental condition. To assess the impact of IGFBP-4 on tumor angiogenesis, M21 cells overexpressing IGFBP-4 (M21BP4) and control-transfected (empty vector) cells (M21Con) were injected subcutaneously into nude mice and early tumor development and angiogenesis was examined 7 days later. At the end of the 7-day assay, mice were killed and tumors were harvested leaving the surrounding mouse skin intact. The number of vessels infiltrating the tumor from the surrounding mouse skin from each experimental condition was quantified using a dissecting scope. Experiments were completed twice with 5-6 tumors from each condition. To examine the impact of blocking tumor-associated avb3 has on tumor angiogenesis, M21 melanoma cells (1.0 or 5.0 9 10 6 ) were injected subcutaneously into nude mice. Three days later, mice were either not treated or injected (i.p) either daily (100 lg) or on days 3 and 5 (50 lg) with human-specific anti-avb3 Mab LM606 or a non-specific normal mouse control antibody. At the end of the 7-day assay, mice were killed and the subcutaneously growing tumors were harvested, and angiogenesis quantified as described above. Experiments were performed twice with 5-6 tumors from each condition.
MicroCT analysis of tumor vascular volume
MicroCT analysis was carried out essentially as described with some modifications [43] . Mice were anesthetized, and the thoracic cavity was opened exposing the heart. The right atrium was opened to serve as a drain vent. The animals were perfused with microfil medium mixture (Microfil MV-122, Flow Tech; Carver, MA) through the left ventricle at 3 ml/min. The animals were killed and placed at 4°C overnight, to allow polymerization of microfil. After perfusion and solidification of the microfil contrast medium, tumors were dissected and scanned using a MicroCT unit (Scanco VivaCT-40, Scanco Medical, Basserdorf, Switzerland). Tumors were scanned at 10.5-lm resolution, with a voltage of 55 kVp and a current of 145 lA. A resolution was set to create a 2,048 9 2,048 pixel image matrix. The tomograms were globally thresholded based on X-ray attenuation and used to render binarized 3-D images of the tumors.
Western blot analysis
Equal numbers of tumor cells from each experimental condition were harvested, and whole cell lysates and conditioned medium (CM) were collected after 24 or 48 h and concentrated 10X. For collection of CM following treatment with inhibitors, equal numbers of M21 cells were incubated with MMP inhibitor GM6001 (0-10.0 lM), the MMP-2 selective ARP 100 inhibitor (41) or DMSO for 48 h. For cell lysates, equal numbers of tumor cells from each experimental condition were washed and lysed in RIPA buffer (Santa Cruz) supplemented with protease inhibitor cocktail. Equal amounts (15-40 lg/lane) of cell lysates or CM were separated by SDS PAGE and transferred to PVDF membranes. Membranes were probed with antibodies directed to IGFBP-4, IGFBP-7, collagen, P38 MAPK, MMPs or tubulin. Western blots were visualized by chemiluminescence detection. Western blots were scanned, and fold change in band intensity was determined using Image J software (NIH).
Statistical analysis
Statistical analysis was performed using the InStat statistical program. Data were analyzed for statistical significance using Student T test. P values\0.05 were considered significant.
Results

Expression of avb3 integrin has minimal effects on tumor cell growth in vitro
Studies indicate that avb3 regulates tumor and endothelial cell behavior through multiple mechanisms [6, 13, 27] . While avb3 expressed in blood vessels plays a role in endothelial cell survival and angiogenesis, its expression in melanoma has been correlated with increased invasion and metastasis [6, 13, 27] . Previously, avb3 expressing M21 melanoma cells were shown to form larger tumors in mice as compared to M21L cells lacking av, yet these cell variants exhibited minimal difference in growth rates in vitro [44] . To confirm these findings, we examined the growth of M21 cells expressing (M21 avb3?) or lacking (M21L avb3-) avb3 integrin in vitro. Consistent with previous studies [44] , little if any change in growth was observed between these cell variants (Fig. 1a) . These results are consistent with the possibility that melanoma cell-associated avb3 may alter the growth properties of these tumors by mechanisms that depend in part, on elements found within the tumor microenvironment. In this regard, we sought to determine whether the differential effects of avb3 on tumor cell growth in vivo were limited to M21 cells. To this end, ECV carcinoma cells were FAC sorted with anti-avb3-specific antibody LM609 to obtain a subpopulation (ECVL) lacking cell surface expression of avb3. As shown in Fig. 1b , while ECV cells readily expressed integrin avb3, 4 rounds of negative sorting resulted in isolation of ECVL cells that expressed little in any cell surface-avb3. To confirm our previous results and to assess the effects of avb3 on carcinoma cells, we examined the growth of these variants in vitro. As shown in Fig. 1c , little change in growth was observed between these ECV carcinoma cell variants.
Expression of avb3 integrin differentially alters tumor growth in vivo
To determine whether avb3 alters tumor growth in vivo, nude mice were injected subcutaneously with M21 and M21L cells and tumors were allowed to grow over a time course. As shown in Fig. 2a , the growth of tumors expressing avb3 (M21) were accelerated resulting in significantly (P \ 0.05) larger tumors as compared to tumors lacking avb3. In similar studies, the effects of avb3 on formation of small early-stage tumors resulting from injection of a lower number (0.5 9 10 6 ) of tumor cells were carried out. Consistent with our previous results, M21 tumors expressing avb3 were significantly (P \ 0.05) larger as compared to M21L tumors lacking avb3 (Fig. 2b) . To confirm that the small M21L tumors that formed remained avb3-negative, tumor sections were stained with Mab LM609 specific for human, but not mouse integrin avb3.
As shown in Fig. 2c , while viable tumors arising from M21 cells readily expressed avb3, viable M21L tumors lacked detectable expression of avb3. In similar studies, we examined the growth of ECV carcinoma cell variants in vivo. Consistent with our previous observations with M21 cells, ECVL carcinoma cells selected for lack of surface expression of avb3 also formed small viable tumors in vivo that were significantly (P \ 0.05) reduced in size as compared to ECV cells (Fig. 2d, e) . Importantly, these ECVL tumors also exhibited reduced levels of avb3 expression as compared to the parental ECV tumors (Fig. 2f) . These data are in good agreement with previous studies and suggest that the differential impact of avb3 on tumor growth in vivo is not restricted to M21 melanoma cells.
While a number of mechanisms may contribute to the early growth advantage of avb3 expressing tumors in vivo, a possibility that has not been studied in detail involves the ability of avb3 to alter the angiogenic output of these tumors. Thus, we examined the relative levels of angiogenesis in tumors expressing or lacking avb3. As shown in Fig. 2g , h, avb3-expressing tumors had a significant (P \ 0.05) 2.0-2.5-fold increase in CD31-expressing blood vessels within equivalent 2009 microscopic fields as compared to those tumors lacking avb3. Finally, to examine whether soluble factors generated from the tumor cell variants may alter endothelial cell behavior, we examined the effects of conditioned medium (CM) from either M21 or M21L cells on the growth of human umbilical vein endothelial cells (HUVEC). As shown in Fig. 2i , addition of CM from M21L cells to HUVECs resulted in significantly (P \ 0.05) reduced growth as compared to CM prepared from M21 cells. These data are consistent with differential expression of angiogenic regulatory molecules from these tumor variants.
Enhanced expression of IGFBP-4 in melanoma cells lacking avb3
Previous studies have suggested that small early-stage tumors may remain dormant and fail to expand without an adequate blood supply [5, [7] [8] [9] [10] . While a number of mechanisms might explain the enhanced angiogenesis associated with avb3 expressing tumors in vivo, it is possible that avb3 may regulate vascularization and subsequent tumor growth in part by modulating expression of endogenous angiogenesis regulatory molecules. Indeed, we previously demonstrated that endothelial cell interaction with denatured collagen, an important avb3 ligand expressed selectively within the tumor microenvironment of melanomas, suppresses the expression of IGFBP-4 [37] . IGFBP-4 has been suggested to regulate tumor growth and angiogenesis [37] [38] [39] [40] 45] . However, the mechanism by which binding to denatured collagen regulates IGFBP-4 expression is not known. Given the ability of avb3 to bind denatured collagen, we first examined IGFBP-4 mRNA levels in M21 and M21L cells. As shown in Fig. 3a , the levels of IGFBP-4 mRNA in M21L cells were enhanced as compared to M21 cells. To confirm the differential expression of IGFBP-4 between avb3 expressing cell variants, conditioned medium (CM) and cell lysates (LY) were examined. As shown in Fig. 3b , an approximately fourfold increase in the relative levels of IGFBP-4 was detected in CM and a twofold increase was observed in whole cell lysates of M21L cells lacking avb3 as compared to M21 cells expressing avb3. These findings are consistent with a possible role for avb3 in regulating expression of IGFBP-4.
Knock down of b3 integrin enhances expression of IGFBP-4 in M21 cells and reduces tumor growth and angiogenesis in vivo
The lack of avb3 in M21L cells results from the lack of the av integrin chain, and thus, it is possible that additional av containing integrins might also contribute the altered expression of IGFBP-4 in our studies. To further examine the role of avb3 in regulating IGFBP-4, we knocked down expression of the b3 integrin in M21 cells (M21b3-KD) by shRNA. As shown in Fig. 4a , the expression of b3 was reduced by greater than 85 % in M21b3-KD cells as compared to control-transfected M21 cells (M21Cont). To confirm the involvement of b3 integrin in the regulation of IGFBP-4 expression, we examined the relative levels of IGFBP-4 mRNA in these cell variants. As shown in Fig. 4b , an approximate fourfold increase in mRNA expression of IGFBP-4 was detected in M21b3-KD as compared to control-transfected M21 cells (M21Cont). To study these b3 integrin knocked down M21 cells in more detail, M21b3-KD cells were injected subcutaneously in mice and tumor growth was examined. As shown in Fig. 4c , M21b3-KD cells exhibited similar growth properties in vivo as was observed with M21L cells lacking avb3 and formed significantly smaller (P \ 0.05) tumors as compared to M21Cont cells. While M21b3-KD lesions were smaller than M21Cont, these tumors contained viable cells (Fig. 4c bottom panel) . Reduced tumor vascular density was also observed in M21b3-KD tumors as compared to control tumors (Fig. 4d) . Finally, to confirm changes in tumor-associated angiogenesis among these tumor variants, we quantified total vascular volumes using lCT scanning [43] . As shown in Fig. 4e , a significant (P \ 0.05) approximately 50 % reduction in total vessel volume was observed in M21b3-KD tumors as compared to M21Cont tumors following normalization for tumor size.
Over-expression of IGFBP-4 in M21 cells reduces melanoma-associated angiogenesis in vivo
Previous studies have suggested that IGFBP-4 may inhibit endothelial tube formation in vitro and angiogenesis in vivo [38] [39] [40] . Moreover, our previous studies suggested that human biopsies of metastatic melanomas, which are often associated with high levels of angiogenesis, exhibited lower levels of IGFBP-4 as compared to primary melanomas [46] . To assess whether the elevated levels of angiogenesis observed within M21 tumors may be associated in part with altered levels of IGFBP-4, we overexpressed IGFBP-4 in M21 cells. As shown in Fig. 5a , M21 cells transfected with an IGFBP-4 expression construct had high levels of IGFBP-4 in conditioned medium (CM) and in whole cell lysates (LY), while little IGFBP-4 was detected in cells transfected with a control construct. To examine these cell variants in more detailed, IGFBP-4 overexpressing and control-transfected cells were injected into mice and allowed to form small early-stage tumor for 7 days and angiogenesis was assessed. As shown in Fig. 5b (top panel), M21Con tumors were associated with numerous blood vessels infiltrating the tumors from the surrounding skin, while IGFBP-4 overexpressing (M21BP4) tumors showed reduced blood vessels. While M21BP4 tumors were smaller than control M21Con tumors, these lesions still contained viable tumor cells (middle panel).
b Fig. 2 Differential impact of avb3 integrins on tumor growth and tumor angiogenesis in vivo. Nude mice were injected with tumor cells, and early-stage tumor growth and angiogenesis were examined. a M21 cell variants (5.0 9 10 6 ) were injected subcutaneously, and tumor growth monitored over a 19-day time course. Data bars represent mean tumor volumes ± SE from 8 to 9 mice per condition. b M21 cell variants (0.5 9 10 6 /mouse) were injected subcutaneously, and tumor growth examined on day 7. c Representative examples of tumor tissues analyzed by H&E staining (Top) and for expression of avb3 (bottom) from each M21 tumor variant. Red color (bottom panels) indicates expression of avb3. Photographs were taken at 9200 magnification. d, e ECV cell variants (5.0 9 10 6 /mouse) were injected subcutaneously into nude mice, and tumor growth examined on days 4 (d) and 14 (e). f Representative examples of tumor tissues analyzed by H&E staining (Top) and for expression of avb3 (bottom) from each ECV tumor variant. Red color (bottom panels) indicates expression of avb3. Photographs were taken at 9200 magnification. g, h Analysis of tumor-associated angiogenesis. Top panels Representative examples of CD31 expressing tumor vessels (Red) from each tumor variant. Photographs were taken at 9200 magnification. Bottom panels Quantification of tumor-associated CD31 expressing blood vessels. Data bars represent mean vessel counts ± SE per 9200 fields (n = 10) for each of three independent tumors from each condition. i The effects of serum-free 910 conditioned medium (CM) from M21 or M21L cells on human umbilical vein endothelial cell (HUVEC) proliferation were examined. Data bars represent mean cell proliferation following incubation with CM from each cell variant, expressed as percent of control ± SE from four independent experiments. *Indicates P values \0.05
Angiogenesis (2015) 18:31- 46 37 Quantification (Fig. 5b bottom panel) of vessels infiltrating these tumors indicated significantly (P \ 0.05) reduced levels associated with M21BP4 tumors as compared to controls. Given the small size of these tumors, we carried out additional experiments by injecting mice with larger numbers of tumor cells to allow quantification of tumor size. As shown in Fig. 5c (top panel), while early-stage M21BP4 tumors were slightly smaller than control M21 tumors, this small change in tumor size did not meet statistical significance (P [ 0.05). However, results from quantification of M21BP4 tumor blood vessels indicated a significant reduction as compared to control tumors (Fig. 5d ).
Reduction of IGFBP-4 in M21 cells expressing avb3 involves altered levels of p38 MAPK
Integrins are known to regulate multiple signaling cascades including the MAP kinase signaling pathways. Previous studies have implicated avb3 in the regulation of P38 MAPK signaling in melanoma and endothelial cells [47, 48] . Therefore, to begin to assess possible mechanisms to account for the altered IGFBP-4 in M21 cell variants, we first examined whether changes in avb3 expression in M21 cells were associated with altered MAP kinase levels. Melanoma cell variants were examined for levels of phosphorylated Erk and p38 MAPK. As shown in Fig. 6a , little change was observed between the levels of phosphorylated Erk in M21 and M21L cells. Interestingly, M21L cells exhibited an approximately 75 % reduction in the levels of phosphorylated p38 MAPK. Surprisingly, reduced levels of total p38 MAPK were also observed, suggesting a distinct change in the p38 MAPK levels in these melanoma cells. Given that multiple isoforms of p38 MAPK exist, we examined whether the reduction in p38 MAPK expression was associated with changes in specific isoforms. As shown in Fig. 6b , while a small reduction in the levels of p38c was observed in M21L cells as compared to M21 cells, no change in the levels of p38b was observed. In contrast, an approximately 70 % reduction in the relative levels of p38a was observed in M21L cells as compared to M21 cells. These findings suggest that the reduction of total p38 was at least in part due to a reduction of p38a.
To examine whether the avb3-associated reduction of IGFBP-4 may be dependent in part on p38 MAPK, we treated avb3 expressing M21 cells with a p38 MAPK inhibitor and examined the relative levels of IGFBP-4. As shown in Fig. 6c , inhibition of p38 MAPK in M21 cells resulted in an approximately 2.6-fold increase in IGFBP-4 protein. Interesting, while inhibiting p38 enhanced the levels of IGFBP-4 protein, only a minimal change in the levels of mRNA was observed (Fig. 6d) . These findings are consistent with a possible role for p38 MAPK in regulating the levels of IGFBP-4 protein by mechanisms associated in part with post-transcriptional events.
The p38 MAPK-associated reduction of IGFBP-4 depends on altered MMP levels An important post-translational mechanism known to regulate IGFBP-4 is proteolytic degradation [49, 50] . Given previous studies implicating P38 MAPK in regulating matrix metalloproteinases (MMPs) and the ability MMPs to degrade IGFBP-4, we examined the relative levels of MMPs in cells expressing or lacking avb3. While minimal levels of MMP-9 were detected in M21 cell variants, MMP-2 was readily detected and exhibited differential expression between M21 cell variants. As shown in Fig. 7a , M21L cells exhibited greater than 50 % reduced levels of MMP-2 as compared to M21 cells as indicated by scanning image analysis of multiple experiments. Similar results were observed in conditioned medium when comparing M21b3-KD cells lacking avb3 to control-transfected M21Con-KD cells (Fig. 7b) . While enhanced level of IGFBP-4 was detected in M21b3-KD cells (Fig. 4) , IG-FBP-7 levels appeared reduced in cells in which b3 integrin was reduced (Fig. 7b) . However, the levels of collagen in these condition medium samples were not changed. Given that little if any change in IGFBP-7 expression was detected between M21 and M21L cells, it is not clear why knocking down b3 integrin chain was associated with reduced levels of IGFBP-7. Consistent with previous studies [51, 52] indicating the ability of p38 MAPK to regulate MMP expression, incubation of M21 cells with the p38 MAPK inhibitor reduced levels of MMP-2 by approximately 40 % as compared to control (Fig. 7c) . While it is known that several proteases including multiple members of the MMP family [49, 50] can degrade IGFBP-4, given the differential expression of MMP-2 observed, we examined whether MMPs might contribute to the loss of IGFBP-4 in our studies. In this regard, we examined the effect of adding a broad spectrum MMP inhibitor (GM6001) on the level of IGFBP-4 in conditioned medium of M21 melanoma cells in which little IGFBP-4 is normally detected. As shown in Fig. 7d , incubation of cells with the MMP inhibitor increased detectable levels IGFBP-4. In a similar study, we examined the effects of the MMP-2 selective inhibitor ARP 100, which has been shown to exhibit minimal inhibitory activity toward other MMPs [41] on the levels of IGFBP-4. As shown in Fig. 7e , incubation of ARP 100 with M21 cells also enhanced detection of IGFBP-4. Importantly, while we cannot completely rule out that other MMPs in addition to MMP-2 contribute to the degradation of IGFBP-4 in M21 cells, our findings are consistent with the ability of p38 MAPK to regulate the levels of IGFBP-4, in part by an MMP-associated mechanism.
Specific blockade of tumor cell-associated avb3 inhibits pathological angiogenesis in vivo Numerous studies have provided evidence for a role for avb3 expressed in endothelial cells in regulating angiogenesis [27] [28] [29] [30] [31] . Interestingly, the role of avb3 in governing blood vessel development is complex as studies have suggested that avb3 may regulate vessel formation in both positive and negative fashion depending the cell types expressing the integrin and the tissue microenvironment in which angiogenesis is occurring. While the majority of studies have shown that pharmacological blockade of avb3 expressed within the endothelial cell compartment can inhibit endothelial cell proliferation and induce apoptosis, little evidence is available for the possibility that avb3 expressed within the tumor cell compartment may actively modulate angiogenesis.
To examine the effects of blocking avb3 expressed specifically within the tumor cell compartment, we examined the effects of anti-human avb3 Mab LM609 on tumor angiogenesis in mice. Importantly, it is well established that Mab LM609 does not bind or inhibit avb3 expressed on mouse blood vessels, yet readily binds and inhibits avb3 expressed on human M21 cells [29, 44] . This important differential binding characteristic allows us the ability to examine whether selective inhibition of avb3 expressed within melanoma cells rather than the murine stromal cell may impact tumor angiogenesis. To test this, mice were injected subcutaneously with avb3 expressing M21 cells. Following a 3-day incubation period, mice were either untreated or treated daily with anti-avb3 Mab LM609 or control antibody for 4 days. The resulting tumors were dissected and analyzed on day 7. Interestingly, even though Mab LM609 does not have the ability to bind and inhibit avb3 expressed in murine endothelial cells, reduced levels of blood vessels were observed infiltrating the tumors from mice injected with Mab LM609 as compared to controls ( Fig. 8a top panel) . While the M21 tumor from mice treated with Mab LM609 appeared smaller, these lesions contained viable tumor cells (Fig. 8a bottom panel) . Given the small size of the tumors, we next carried out similar experiments and injected mice with increased numbers (5.0 9 10 6 ) of tumor cells to allow the formation of larger tumors within the 7-day incubation period. Mice were again untreated or treated with Mab LM609 or control, and tumor volumes and angiogenesis quantified on day 7. As shown in Fig. 8c , while tumors from mice treated with Mab LM609 were smaller than controls, this reduction did not meet statistical significance (P [ 0.05). However, consistent with our previous results, tumors from mice treated with Mab LM609 exhibited significantly (P \ 0.05) reduced levels of blood vessels as compared to controls (Fig. 8d) . These data are consistent with the possibility that early blockade of avb3 expressed specifically within the tumor cells contributes to suppressing the angiogenic switch within these human melanoma cells.
Discussion
Recent evidence suggests that avb3 plays diverse roles in regulating cell behavior as targeting of this integrin in endothelial cells inhibits adhesion, migration and survival in vitro [25, [27] [28] [29] [30] [31] . Pharmacological inhibition of avb3 has also been shown to inhibit pathological angiogenesis in vivo using multiple models [27] [28] [29] [30] [31] . Interestingly, in other studies, lack of avb3 expression in mutant mice was associated with limited impact on normal vascular development [30, 31] . Surprisingly, studies have also shown that angiogenesis and tumor growth in mutant mice lacking b3 were enhanced, and this enhanced angiogenesis was associated with altered VEGFR signaling [53] . In one set of studies, enhanced but non-functional blood vessel formation was observed in mice expressing signaling deficient b3 integrin [54] , while in a separate study investigators observed reduced pathological angiogenesis and smaller tumors in b3 signaling deficient mice, which was associated with reduced recruitment of bone marrow-derived stromal cells to the tumor and associated vasculature [34] . Interestingly, recent findings have also indicate that the role of avb3 integrin in angiogenesis may be time dependent as reduction of avb3 inhibited angiogenesis and subsequent tumor growth at an early time point but had little effect on later-stage tumors with pre-established vessels [55] . Given these findings, the divergent roles of avb3 may depend on a combination of distinct parameters such as the particular cell type expressing the integrin, the type and accessibility of avb3 ligands, the activation state of the integrin and the relative composition of secreted growth factors found locally within the tissue microenvironment in which angiogenesis is occurring [56] . In this regard, antagonists of avb3 inhibited FGF-2-induced angiogenesis while exhibiting minimal activity on angiogenesis induced by VEGF [57] .
In agreement with context-dependent functions of avb3, activated avb3 in tumor cells growing within the brain microenvironment resulted in enhanced pathological angiogenesis and elevated levels of VEGF, resulting from a mechanism associated with the inhibition of the translational repressor 4E-binding protein-1 (4E-BP1) [58] . These same tumor cells expressing activated avb3 growing within the mammary fat pad failed to exhibit a similar response [58] . These findings are consistent with the concept that the particular tissue microenvironment in which avb3 is expressed may impact its ability to alter the angiogenic output of a given tumor and thus the angiogenic switch. Consistent with this possibility, studies have suggested that avb3-dependent interactions with the ECM may regulate shear stress-induced release of FGF-2 from endothelial cells [59] . Here we provide evidence that M21 melanoma cells as well as ECV carcinoma cells expressing avb3 formed significantly larger tumors with elevated levels of angiogenesis as compared to corresponding tumor cells that lacked avb3. Given that avb3 expressing tumor cell variants exhibited similar growth properties in vitro, it is likely that the formation of these small early-stage tumors in our studies depends on additional mechanisms regulated by factors governed in part by the local microenvironment. To this end, we provide evidence that the expression of the endogenous angiogenesis inhibitor IGFBP-4 is controlled in part by avb3 in M21 cells. These findings are consistent with our previous report, indicating a reduction in tumorassociated IGFBP-4 in biopsies of metastatic human melanomas as compared to primary melanoma [46] , given that metastatic melanoma have been shown to express high levels of avb3 as compared to primary melanoma. This avb3-mediated reduction of IGFBP-4 in melanoma cells depends in part on p38 MAPK since L21L cells lacking avb3 exhibited reduced levels of p38a and elevated levels of IGFBP-4. Moreover, blocking p38 activation in avb3 expressing M21 cells enhanced the levels of IGFBP-4. The ability of p38 MAPK to alter IGFBP-4 levels appears to depend on post-transcriptional events as minimal changes in IGFBP-4 mRNA were observed, yet the levels of IG-FBP-4 protein were enhanced by 2.6 fold. In this regard, p38 MAPK has been suggested to regulate the expression of MMPs, and MMPs can degrade IGFBP-4 [49, 50] . Our studies indicate elevated expression of MMP-2 and little detectable IGFBP-4 in conditioned medium of M21 cells, while enhanced levels of IGFBP-4 were observed in conditioned medium from M21L cells that lacked avb3 and that expressed reduced levels of p38 MAPK and MMP-2. Importantly, blocking p38 MAPK in M21 cells reduced levels of MMP-2 and enhanced levels of IGFBP-4. Moreover, blocking MMP activity with either a broad spectrum MMP inhibitor or an MMP-2 selective inhibitor resulted in the enhanced accumulation of IGFBP-4 in M21 cells. These novel findings are consistent with a mechanism by which p38 MAPK contributes to the regulation of IGFBP-4 by altering MMP-mediated degradation. It would be interesting to speculate that given that avb3 expressing metastatic melanoma cells have been suggested to express high levels of MMPs, the reduction in the endogenous angiogenesis inhibitor IGFBP-4 expression observed in our previous studies [46] might be associated in part with enhanced MMP-mediated degradation. Our studies suggest that the elevated levels of IGFBP-4 in melanoma cell variants lacking avb3 (M21L and M21b3-KD) may contribute to the reduction in the early onset of angiogenesis and the smaller tumor size observed with these melanomas. In support of this possibility, avb3 expressing M21 cells overexpressing IGFBP-4 exhibited reduced tumor growth and angiogenic response as compared to avb3-positive M21 cells expressing the control vector. While it is possible that additional secreted factors regulated by avb3 in these cells contribute to the differential angiogenic output, overexpression of IGFBP-4 in M21 cells inhibited melanoma-associated angiogenesis in vivo.
Interestingly, previous studies have indicated that av integrins expressed in melanoma cells as well as in endothelial cells can suppress p53 activity [60, 61] . P53 has been shown to play an important role in regulating the angiogenic switch in tumors by enhancing the expression of pro-angiogenic factors such as FGF-2, HIF1a, VEGF and PDGF and by reducing the expression of endogenous angiogenesis inhibitors such as TSP-1 and prolyl hydroxylase leading to reduced levels anti-angiogenic collagen fragments [62] . These findings are consistent with the possibility that the accelerated early tumor growth observed with melanoma cells expressing avb3 may be associated with avb3-dependent activation of a proangiogenic program resulting from altering the balance of pro-angiogenic factors and endogenous angiogenesis inhibitors. Moreover, the importance of avb3 expressed within the melanoma cell compartment in regulating the angiogenic switch is further supported by our observations that targeting tumor cell-associated avb3, but not other murine host cells, resulted in a reduction of early onset tumor angiogenesis. Taken together, our studies provide new insight into the context-dependent role of avb3 in controlling the balance of angiogenic regulatory factors, which may contribute to the overall control of early melanoma tumor growth.
